Chiesi Group Completes Acquisition of KalVista Pharmaceuticals for $27.00/Share; Stock Delisted
KALV has more than doubled off its 52-week low of $9.83.
Summary
KalVista Pharmaceuticals has been acquired by Chiesi Group for $27.00 per share, marking the completion of the tender offer and merger. The company's stock will now be delisted from Nasdaq.
Key Events · M&A and Partnerships · KALV
-
Acquisition Completed
Chiesi Group has finalized its acquisition of KalVista Pharmaceuticals, Inc., making it a wholly-owned subsidiary.
-
Tender Offer Successful
Approximately 77.8% of KalVista's outstanding shares were validly tendered and accepted for payment at $27.00 per share.
-
Merger Finalized
Following the tender offer, a merger was completed, converting all remaining outstanding shares into the right to receive $27.00 per share in cash.
-
Stock Delisted
KalVista's common stock has ceased trading on the Nasdaq Global Market and will be deregistered under the Exchange Act.
Analysis · KALV · Life Sciences
This filing confirms the definitive completion of the acquisition of KalVista Pharmaceuticals by Chiesi Group. The tender offer was successful, with 77.8% of shares tendered, and the subsequent merger means KalVista is no longer an independent public entity. This is a thesis-altering event for investors, as the company's stock will be delisted, and all shareholders will receive $27.00 per share in cash, representing a successful exit at a premium.
At the time of this filing, KALV was trading at $27.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $9.83 to $27.00. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.